New drug Aplidin
Zeltia SA unit PharmaMar SA said further investigation of its Aplidin drug in the treatment of multiple myeloma is 'warranted,' given the risk benefit profile of the drug.
In a press release relating to the Phase II results of Aplidin in patients with advanced multiple myeloma at the American Society of Hematology in Atlanta, Georgia, PharmaMar said the findings 'confirm the potential role of Aplidin as a single agent therapy in this indication.'
In a press release relating to the Phase II results of Aplidin in patients with advanced multiple myeloma at the American Society of Hematology in Atlanta, Georgia, PharmaMar said the findings 'confirm the potential role of Aplidin as a single agent therapy in this indication.'
posted by gwg at 9:37 PM
0 Comments:
Post a Comment
<< Home